FIELD: medicine.
SUBSTANCE: invention relates to a method of treatment or relieving the severity of cystic fibrosis in a patient, where the patient has the cystic fibrosis transmembrane receptor (CFTR) with R117H mutation, including a stage of introduction to the said patient of an effective quantity of N-(5-hydroxy-2,4-ditert-butyl-phenyl)-N-methyl-4-oxo-1H-quinoline-3-carboxamide.
EFFECT: elaborated is the method of treating cystic fibrosis, based on the application of N-(5-hydroxy-2,4-ditert-butyl-phenyl)-N-methyl-4-oxo-1H-quinoline-3-carboxamide.
3 cl, 4 tbl, 30 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TRKA KINASE INHIBITORS, COMPOSITIONS BASED THEREON AND METHODS | 2015 |
|
RU2672583C2 |
| MODULATORS OF ATP-BINDING CARTRIDGE TRANSPORTERS | 2005 |
|
RU2528046C2 |
| METHOD OF MODULATING TRANSPORTERS OF ATP-BINDING CASSETTE | 2005 |
|
RU2525115C2 |
| ATP-BINDING CASETTE TRANSPORTER MODULATORS | 2005 |
|
RU2382779C2 |
| PRIMARY CARBOXAMIDES AS BTK INHIBITORS | 2014 |
|
RU2708395C2 |
| MODULATORS OF NUCLEAR RECEPTORS | 2016 |
|
RU2715897C2 |
| TREATMENT METHOD | 2012 |
|
RU2621148C2 |
| MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | 2005 |
|
RU2556984C2 |
| HETEROCYCLIC DERIVATIVES AND USE THEREOF | 2014 |
|
RU2681849C2 |
| MINERALOCORTICOID RECEPTOR ANTAGONISTS | 2012 |
|
RU2598842C2 |
